||This article needs attention from an expert in Pharmacology. (March 2010)|
|Chemical and physical data|
|Molar mass||5823 g/mol|
|(what is this?)|
Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. It was developed by Sanofi-Aventis and is sold under the trade name Apidra. When injected subcutaneously, it appears in the blood earlier than human insulin. When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal. Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.
- DailyMed: apidra (insulin glulisine) injection, solution
- Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
- Garnock-Jones, K. P.; Plosker, G. L. (2009). "Insulin Glulisine". Drugs. 69 (8): 1035–1057. PMID 19496630. doi:10.2165/00003495-200969080-00006.
- Drugs.com: Insulin Glulisine
- "Sanofi Prescription Products" (PDF). Sanofi. Retrieved 21 April 2012.
|last1=in Authors list (help)